These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6666223)

  • 1. Newer aspects of the pharmacokinetics of organic nitrates.
    Chasseaud LF
    Z Kardiol; 1983; 72 Suppl 3():20-3. PubMed ID: 6666223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
    Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isosorbide 5-mononitrate pharmacokinetics in humans.
    Taylor T; Chasseaud LF; Major R; Doyle E; Darragh A
    Biopharm Drug Dispos; 1981; 2(3):255-63. PubMed ID: 7295882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of organic nitrates.
    Bogaert MG
    Clin Pharmacokinet; 1983; 8(5):410-21. PubMed ID: 6414751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
    Geigenberger A; Degen J; Maier-Lenz H
    Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.
    Straehl P; Galeazzi RL; Soliva M
    Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
    Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
    Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isosorbide 5-mononitrate kinetics.
    Major RM; Taylor T; Chasseaud LF; Darragh A; Lambe RF
    Clin Pharmacol Ther; 1984 May; 35(5):653-9. PubMed ID: 6713775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and bioavailability of isosorbide-5-mononitrate in humans.
    Rameis H; Bacher S; Eichler HG; Horwatitsch H
    Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):678-80. PubMed ID: 4093207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isosorbide 5-mononitrate pharmacokinetics.
    Chasseaud LF
    Cardiology; 1987; 74 Suppl 1():6-11. PubMed ID: 3300979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
    Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF
    Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions.
    Morrison RA; Fung HL
    J Pharmacol Exp Ther; 1984 Oct; 231(1):124-30. PubMed ID: 6491969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects.
    Taylor T; Chasseaud LF; Doyle E; Darragh A; O'Kelly DA; Fitzgerald D
    Biopharm Drug Dispos; 1980; 1(3):149-56. PubMed ID: 7448342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.
    Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T
    Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.
    Abshagen U; Betzien G; Endele R; Kaufmann B; Neugebauer G
    Eur J Clin Pharmacol; 1985; 27(6):637-44. PubMed ID: 3987768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption and excretion of isosorbide dinitrate and isosorbide-2-mononitrate in dogs.
    Cayen MN; Hicks D; Karounis J; Dvornik D
    J Pharm Pharmacol; 1983 May; 35(5):312-6. PubMed ID: 6134800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
    Schaumann W
    Int J Clin Pharmacol Ther Toxicol; 1989 Sep; 27(9):445-53. PubMed ID: 2681004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard).
    Neugebauer G; Akpan W; Stemmle B; Jaeger H; Mosberg H; Lutz D
    Int J Clin Pharmacol Ther Toxicol; 1989 Jan; 27(1):34-8. PubMed ID: 2744904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.
    Santoni Y; Iliadis A; Cano JP; Luccioni R; Frances Y
    J Pharmacokinet Biopharm; 1986 Feb; 14(1):1-17. PubMed ID: 3746630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic extraction of isosorbide dinitrate in cardiac patients.
    Morrison RA; Wiegand UW; Jähnchen E; Höhmann D; Kasper W; Meinertz T; Fung HL
    Clin Pharmacol Ther; 1983 Dec; 34(6):724-31. PubMed ID: 6641086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.